Abstract

Some have argued that placebo-controlled trials (PCTs) are unnecessary and unethical in conditions such as asthma for which there is standard therapy. This article, by using asthma clinical trials as an example, examines the ethics of PCTs. There remain several scientifically sound reasons to conduct PCTs: (1) ensuring scientific validity of the trial, (2) evaluating new therapies less effective than the gold standard, (3) minimizing the number of patients exposed to potentially inefficacious or dangerous therapy, (4) studying clinical situations in which withdrawal of therapy might be considered, and (5) determining the true incidence of side effects. Opponents of PCTs err by conflating clinical research with clinical practice and ignoring the fact that all clinical research involves some sacrifice on the part of the subject for the ends of the research and the good of future patients. PCTs do not per se violate major ethical codes. Properly conducted, PCTs remain a valuable and ethical tool in the armamentarium of modern scientific medicine.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.